Blog Posts

Concurrences Law & Economics: M&A Unlocks Economies of Scale and Scope Across the Life Sciences Ecosystem

Concurrences Law & Economics: M&A Unlocks Economies of Scale and Scope Across the Life Sciences Ecosystem

In a recent article published in Concurrences Law & Economics, Cornerstone Research experts highlight ways that mergers and acquisitions (M&A) can contribute to innovation in the biopharmaceutical industry. Among these, the authors contend that M&A and similar collaborations allow life sciences companies to unlock economies of scale and scope and innovate more efficiently.

read more
Innovations Advanced by M&A: Breakthrough Treatments for Rare, Aggressive Cancers

Innovations Advanced by M&A: Breakthrough Treatments for Rare, Aggressive Cancers

By combining complementary resources and expertise among companies of all sizes – while driving investment across the ecosystem – M&A helps advance innovative new treatments and cures to patients. This was precisely the case for Retevmo and Jaypirica, two first-of-their-kind oncology treatments brought to market through the acquisition of Loxo Oncology by Eli Lilly & Co.

read more
New Research Article: The impact of pharmaceutical M&A on innovation

New Research Article: The impact of pharmaceutical M&A on innovation

Mergers and acquisitions (M&A) play a unique and fundamental role in the development of new treatments and cures across the pharmaceutical ecosystem. A research article published yesterday, “The impact of pharmaceutical M&A on innovation: Insights from the literature” by competition and economics experts from Cornerstone Research, explores this in depth.

read more